Milliardenmarkt Augenlaser VJET,OB Kurs.0.059 - 500 Beiträge pro Seite

[UH1d]

Vorstellung Visijet
gelistet an der OTC
Shares gerade mal 28 Mill.
Symbol VJET.OB
WKN 165219


http://www.advancedrefractive.com/Company.htm

http://www.expertsinternational.com/arons/

Das kalifornische Medizintechnikunternehmen VisiJet Inc. entwickelt innovative Produkte zur Behandlung von Augenkrankheiten mit Fokus auf Linseneintrübungen (Grauer Star) sowie Fehlsichtigkeiten.

Die Hauptprodukte HydroKeratome® und PulsaTome® basieren auf einer eigen entwickelten Wasserstrahltechnologie: Der Mikro-Wasserstrahl ist noch dünner als der Durchmesser eines Haares und schneidet mithilfe von Hochdruck das Augengewebe. Diese Behandlungsmethode bietet einige Vorteile: Geringere Schmerzen, Verbesserung der Sehkraft tritt schneller ein und Narbenbildungen sind seltener.

Anfang Mai 2004 machte VisiJet durch einen cleveren Schachzug auf sich aufmerksam; Man übernahm die weltweiten Vertriebs- und Marketingrechte für die LASIK/Epi-LASIK Produkte der deutschen Gebauer Medizintechnik GmbH. So kann VisiJet schon im zweiten Quartal 2004 erste Umsätze erzielen.


VisiJet Inc., is rebranding the company and will now be doing business as Advanced Refractive Technologies, Inc. (ART). VisiJet is unveiling the Advanced Refractive Technologies name to the ophthalmic community through a series of advertisements in leading ophthalmic trade journals.

As reported by Cataract & Refractive Surgery Today, Anamed, Inc., which has been rebranded as Intralens Vision, Inc. by the firm`s new president and CEO, Randy Alexander, is working toward FDA approval of its intracorneal lens, which is currently undergoing clinical trials in the US for hyperopic corrections of up to +6.00D. Intralens Vision intends to develop, manufacture, and market intracorneal lenses composed of its unique microporous hydrogel material.

VisiJet, Inc., dba Advanced Refractive Technologies (ART), has received approval from the Health Ministry of Japan to market and sell its EpiLift System, a medical device that enables a potentially safer form of laser eye surgery called Epi LASIK. The company also announced that it had signed agreements with three different distributors to market and sell the EpiLift System in Japan, Thailand, Indonesia, Singapore, Malaysia and Brunei.




VisiJet Inc. (OTC BB: VJET), dba Advanced Refractive Technologies (ART), a developer and marketer of innovative technologies for the ophthalmic surgical market, received licensed approval from Health Canada, the federal department responsible for helping the people of Canada maintain and improve their health, to market and sell the EpiLift System in Canada.

The EpiLift System is already being sold in over 30 countries including the United States, Japan and in most countries in Europe. The system is the cornerstone of Epi-LASIK, a new, safer method of the popular LASIK corrective vision surgery.

" Canada is a difficult market to enter due to its stringent safety requirements, which are very similar to those in the United States. Gaining this approval from Health Canada is further testimony to the efficacy and safety of the EpiLift device. It is also an extremely important market that will enable us to expand our North American reach." said Randy Bailey, CEO.

About the EpiLift System

When the EpiLift System is used, the epithelium - the top layer of the eye - is cleanly separated, at a natural division point in the eye, from the Bowman`s layer membrane in an intact sheet of viable tissue. The tissue is then lifted away from the cornea so that a laser can be applied to reshape it. This entire process, Epi-LASIK, produces virtually instant visual results similar to LASIK but with the stable long-term visual outcomes of PRK.

LASIK surgery, currently a standard corrective vision surgical process, requires making a flap in the top layer of the eye before the laser is applied. This flap, once created, never fully heals, which can lead to complications and possible vision impairment in the future. Because it does not involve cutting the cornea or creating a permanent flap, the EpiLift System allows the eye to regrow the connections with the epithelium, resulting in a safer procedure with a significantly lower risk of complications

Wenn sie Fuß fassen sehe ich riesiges Potential

Grüße

[UH1d]

der GROßE Konkurrent

http://finance.yahoo.com/q?s=eye

Gruß

[janolo]

[MFC500]

Hast du dir auch mal die Bilanzdaten des letzten Quartals (31.03.) angeschaut?

11 T Cash
7,3 Mio Schulden
-3,1 Mio Eigenkapital

Sieht nicht sehr vertrauenerweckend aus

[UH1d]

Ja habe ich mir, wenn alles positiv wär wären sie wahrscheinlich auch nicht so günstig.
Wenn sie richtig Fuß fassen sollten, sieht es schnell anders aus.

Diverse Märkte werden in Angriff genommen.

VisiJet, Inc. dba Advanced Refractive Technologies (ART) has received approval from the Health Ministry of Japan to market and sell its EpiLift System, a medical device that enables a potentially safer form of laser eye surgery called Epi-LASIK. The company also announced that it had signed agreements with three different distributors to market and sell the EpiLift System in Japan, Thailand, Indonesia, Singapore, Malaysia and Brunei


VisiJet Inc. dba Advanced Refractive Technologies (ART), received licensed approval from Health Canada, the federal department responsible for helping the people of Canada maintain and improve their health, to market and sell the EpiLift System in Canada


Finanzierungszusage vom Mai


VisiJet, Inc. closed on a financing of $4.9 million. VisiJet plans to use the funds to support marketing and sales of its lead product, the EpiLift System, and to improve its short-term debt structure. The EpiLift System is a new, safer refractive surgery technique that enables ophthalmologists to perform EpiLASIK surgery with fewer postoperative complications than existing methods. Six firms participated in the financing, including Renaissance Capital, Corsair Capital, Roaring Fork Capital Management, Alpha Capital AG, Little Gem Life Sciences, and Liberty View Capital.

The February issue of Ophthalmic Market Perspectives reported on Q4 2004 refractive procedures. According to editor David Harmon, growth in refractive surgery, which had been growing at more than 19% for the first three quarters, slowed during Q4. He remarked that the slowdown was primarily due to weakening consumer confidence during October and November, that delayed decisions for potential LASIK patients. He estimated that the total U.S. laser refractive procedures for the fourth quarter were 276,000, up 7.3% when compared with the 257,200 procedures performed during Q4 2003. When non-laser procedures, including conductive keratoplasty, refractive lens exchange, and phakic IOLs are included, U.S. refractive procedures increased 11.5%. In addition, an estimated 6200 patients traveled to Canada and Mexico bringing total Q4 procedures to 298,200, an overall increase of 11.1%. Overall, Q4 2004 procedures declined 5.1% compared to a seasonally stronger Q3 2004.


Grüße

[UH1d]

Wahnsinn + 8% unter riesen Umsätzen!

[UH1d]

Bitte um kurze Hilfe,habe das gerade gefunden.
Frage,erhöht sich auch die Anzahl der outstanding Shares?
Mein English reicht da nicht.
Danke für Antwort

ADVANCED REFRACTIVE TECHNOLOGIES, INC.
1062 Calle Negocio, Suite D, San Clemente, CA 92673

INFORMATION STATEMENT

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY

INTRODUCTION

This Information Statement is being mailed or otherwise furnished to stockholders of Advanced Refractive Technologies, Inc., a Delaware corporation ("ART" or the "Company"), in connection with the approval, by written consent of the holders of a majority of the Company`s Common Stock, of an amendment to the Certificate of Incorporation of the Company to increase the authorized Common Stock of the Company to 750,000,000 shares.

This Information Statement is being first sent to stockholders on or about July , 2005.

VOTE REQUIRED

The vote which was required to approve the amendment was the affirmative vote of the holders of a majority of the outstanding Common Stock of the Company

The record date for purposes of determining the number of outstanding shares of Common Stock of the Company, and for determining stockholders entitled to vote, was the close of business on June 1, 2005. As of the record date, the Company had 29,856,628 shares of Common Stock outstanding. Holders of the shares have no preemptive rights. Shareholders beneficially owning 15,251,227 shares as of the record date executed written consents approving the amendment.

THE ACTION

On May 12, 2005, the Board of Directors approved, subject to stockholder approval, an amendment to the Company`s Certificate of Incorporation to increase the number of Common Stock which the Company is authorized to issue from one hundred million (100,000,000) shares to seven hundred fifty million (750,000,000) shares. At present, the Certificate of Incorporation provides that the total number of shares the Company has authority to issue is one hundred million (100,000,000) shares of Common Stock and ten million (10,000,000) shares of Preferred Stock. The authorized Preferred Stock is unaffected by the proposed amendment.

Following approval by the Board of Directors, the proposal was approved by the written consents of holders of a majority of the Company`s outstanding common stock.

The change will be accomplished by amending the second sentence of ARTICLE IV of the Company`s Certificate of Incorporation to read as follows:

The total number of shares of Common Stock this Corporation is authorized to issue is 750,000,000, and each such share shall have a par value of $.001.The total number of shares of Preferred Stock this corporation is authorized to issue is 10,000,000, and each such share shall have a par value of $.001.


--------------------------------------------------------------------------------

The Amendment will become effective upon filing the Certificate of Amendment to the Company`s Certificate of Incorporation with the Delaware Secretary of State, anticipated to be approximately twenty-one days after this Information Statement has been distributed to the Company`s stockholders.

The Board of Directors of the Company believes that the amendment is advisable and in the best interests of the Company and its stockholders in order allow it to honor existing equity financing commitments, to provide for conversion of outstanding convertible securities into Common Stock or issuance of shares of Common Stock upon exercise of outstanding options and warrants, and to attract and obtain additional sources of capital in the future pursuant to additional equity financing transactions.

ACTION BY WRITTEN CONSENT

Under Section 228 of the Delaware General Corporation Law, any action which may be taken at any meeting of the stockholders may also be taken without a meeting and without prior notice and without a vote, so long as a consent is signed by the holders of the number of outstanding shares that would be necessary to authorize such action at a shareholders` meeting at which all shares entitled to vote were present and voted (here, a majority of the outstanding shares of Common Stock of the Company